Type 2 diabetes
Conditions
Interventions
Sitaglipitin
Sponsors
Jikei University School of Medicine Kashiwa Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with type 2 diabetes who is treated by insulin mono-therapy or insulin and insulin combined with metformin, SU or pioglitazone therapy. 2)HbA1c >=7.5%, <10.0% JDS 3)Age >=20 years (Male and Female)
Exclusion criteria
Exclusion criteria: 1)Patients with type 1diabetes (fasting C-peptide less than 0.5mg/dL) 2)Patients with severe ketosis, diabetic coma or precoma within 6 months 3)Patients with severe infections, before or after operation, or serious trauma . 4)Patients with exceeding the moderate renal impairment (sCr: male>=1.5mg/dl, female>=1.3mg/dl). 5)Patients receiving GLP-1 analog 6)Patients receiving oral glucose lowering drug without metformin, SU or pioglitazone 7)Patients who are pregnant, breast-feeding and/or intention to become pregnant 8)Patients with allergy against sitagliptin 9)Other patients determined to be inappropriate by physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in responses of glucose, glucagon and C-peptide with sitagliptin treatment examined by OGTT | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of HbA1c, fasting plasma glucose, glucagon and C-peptide before and after sitagliptin treatment | — |
Countries
Japan
Contacts
Public ContactTakashi Sasaki
Jikei University School of Medicine Kashiwa Hospital Division of Diabetes, Metabolism and Endocrinology Department of Internal Medicine
Outcome results
None listed